Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 700 of 866 entries
View as:

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02493855 Org: User:
Start: 06/30/15 End: 12/31/16 Due: 12/31/17

Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice

Phase: N/A Priority: Normal
NCT ID: NCT03155243 Org: User:
Start: 06/20/17 End: 02/24/20 Due: 02/24/21

Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Phase: N/A Priority: Normal
NCT ID: NCT05069597 Org: User:
Start: 10/14/21 End: 08/28/23 Due: 08/28/24

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Phase: N/A Priority: Normal
NCT ID: NCT03212521 Org: User:
Start: 08/07/17 End: 08/13/18 Due: 08/13/19

Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00660673 Org: User:
Start: 11/13/09 End: 11/30/21 Due: 11/30/22

Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04570631 Org: User:
Start: 11/05/20 End: 05/05/25 Due: 05/05/26

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03145948 Org: User:
Start: 05/09/17 End: 08/16/17 Due: 08/16/18

A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

Phase: N/A Priority: Normal
NCT ID: NCT05555979 Org: User:
Start: 12/14/22 End: 04/10/24 Due: 04/10/25

Expanded Access to ABBV-787

Phase: N/A Priority: Normal
NCT ID: NCT06439966 Org: User:
Start: - End: - Due: -

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04401748 Org: User:
Start: 09/10/20 End: 09/10/25 Due: 09/10/26

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

Phase: N/A Priority: Normal
NCT ID: NCT05940402 Org: User:
Start: 07/24/23 End: 12/19/24 Due: 12/19/25

A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)

Phase: N/A Priority: Normal
NCT ID: NCT04509622 Org: User:
Start: 10/05/20 End: 04/15/21 Due: 04/15/22

COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel

Phase: N/A Priority: Normal
NCT ID: NCT03362879 Org: User:
Start: 12/14/17 End: 12/17/18 Due: 12/17/19

Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )

Phase: N/A Priority: Normal
NCT ID: NCT02896985 Org: User:
Start: 12/16/16 End: 03/11/20 Due: 03/11/21

BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence

Phase: N/A Priority: Normal
NCT ID: NCT04073303 Org: User:
Start: 08/29/19 End: 11/10/22 Due: 11/10/23

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02582632 Org: User:
Start: 11/24/15 End: 12/01/16 Due: 12/01/17

Open-label Trial in Parkinson's Disease (PD)

Phase: N/A Priority: Normal
NCT ID: NCT04760769 Org: User:
Start: 02/24/21 End: 01/31/26 Due: 01/31/27

A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06487572 Org: User:
Start: 07/23/24 End: 02/07/25 Due: 02/07/26

Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)

Phase: N/A Priority: Normal
NCT ID: NCT04554966 Org: User:
Start: 04/16/21 End: 08/14/23 Due: 08/14/24

ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02565758 Org: User:
Start: 09/18/15 End: 03/25/19 Due: 03/25/20

Effect of Long-term Psoriasis on Patients' Life - CORONATE

Phase: N/A Priority: Normal
NCT ID: NCT05555953 Org: User:
Start: 01/26/23 End: 10/17/24 Due: 10/17/25

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Phase: N/A Priority: Normal
NCT ID: NCT06895343 Org: User:
Start: 04/03/25 End: 10/31/26 Due: 10/31/27

Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT02669940 Org: User:
Start: 04/15/16 End: 07/04/17 Due: 07/04/18

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

Phase: N/A Priority: Normal
NCT ID: NCT05268068 Org: User:
Start: 06/27/19 End: 04/26/20 Due: 04/26/21

Expanded Access to Telisotuzumab Vedotin

Phase: N/A Priority: Normal
NCT ID: NCT04830202 Org: User:
Start: - End: - Due: -